International Association for the Study of Lung Cancer: LUMINOSITY Trial Demonstrates Telisotuzumab Vedotin Shows Durable Response in Asian Patients With C-Met Protein-Overexpressing EGFR WT Nonsquamous NSCLC
September 11, 2024
September 11, 2024
AURORA, Colorado, Sept. 11 (TNSres) -- The International Association for the Study of Lung Cancer issued the following news release:
(San Diego, Calif.--September 10, 2024, 10:35 a.m.) -- The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing, epidermal growth factor receptor (EGFR) wildtype (WT), locally advanced/metastatic nonsquamous non-small cell . . .
(San Diego, Calif.--September 10, 2024, 10:35 a.m.) -- The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing, epidermal growth factor receptor (EGFR) wildtype (WT), locally advanced/metastatic nonsquamous non-small cell . . .